Answers are grounded in this paper and cite their sources.
When I131-labeled dl-di-iodotyrosine (T2*) is injected intravenously into patients with treated myxedema (1) or into normal subjects (2), labeled iodine which appears in the urine is almost entirely inorganic iodide. Only a small fraction of the administered T2* escapes deiodination. I131-labeled l-mono-iodotyrosine (T1*) is similarly deiodinated; but in the case of labeled d-mono-iodotyrosine, a large fraction appears unchanged in the urine. After ingestion or injection of I131, very little (3) if any (4, 5) labeled free mono- or di-iodotyrosine appears in the serum. Recently both labeled mono-and di-iodotyrosine were detected in large amounts in the serum of a patient with hypothyroidism and familial goiter (6). One possible explanation for this unusual finding was that degradation of these substances might be defective.
No takes yet. Share an insight, caveat, or question.
Stanbury et al. (1956) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: